Skip to main content

Drug Interactions between Focalin XR and Prozac

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

FLUoxetine dexmethylphenidate

Applies to: Prozac (fluoxetine) and Focalin XR (dexmethylphenidate)

MONITOR: Coadministration with methylphenidate may increase the plasma concentrations and effects of selective serotonin reuptake inhibitors (SSRIs). Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of some antidepressants including SSRIs. There have been isolated reports of adverse reactions such as hallucinations, confusion, seizures, and serotonin syndrome during concomitant use of methylphenidate with an SSRI, which resolved following discontinuation of one or both drugs. Nevertheless, the combination has been used therapeutically to improve clinical response in the treatment of attention-deficit hyperactivity disorder and to augment the effects of SSRIs in the treatment of depression.

MANAGEMENT: Pharmacologic response to SSRIs should be monitored more closely whenever methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) is added to or withdrawn from therapy, and the dosage of one or both drugs adjusted as necessary.

References

  1. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO (1996) "Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series." J Clin Psychiatry, 57, p. 72-6
  2. Findling RL (1996) "Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series." J Child Adolesc Psychopharmacol, 6, p. 165-75
  3. Gammon GD, Brown TE (1993) "Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder." J Child Adolesc Psychopharmacol, 3, p. 1-10
  4. Lavretsky H, Kumar A (2001) "Methylphenidate augmentation of citalopram in elderly depressed patients." Am J Geriatr Psychiatry, 9, p. 298-303
  5. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  6. (2002) "Product Information. Concerta (methylphenidate)." Alza
  7. Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 3rd (2006) "Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial." Am J Geriatr Psychiatry, 14, p. 181-5
  8. Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (2008) "Serotonin syndrome induced by augmentation of SSRI with methylphenidate." Psychiatry Clin Neurosci, 62, p. 246
View all 8 references

Switch to consumer interaction data

Drug and food interactions

Moderate

FLUoxetine food

Applies to: Prozac (fluoxetine)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer